{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:03:11Z","timestamp":1793674991639,"version":"4.5.1"},"reference-count":21,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P\u00a0= .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P\u00a0= .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P\u00a0= .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P\u00a0= .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012561","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:18:39Z","timestamp":1719584319000},"page":"3488-3496","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"first","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spyrou","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7955-1119","authenticated-orcid":false,"given":"Nikolaos","family":"Katsivelos","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kowalyk","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Eng","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Kasikis","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahnuma","family":"Beheshti","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Baez","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"4Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[{"name":"5Division of Hematology, James Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Etra","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"6Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"7Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[{"name":"9Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"10Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":false,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"11Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Vasova","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine 5, Hematology\/Oncology, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"13Department of Medicine I - Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Young","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L. M.","family":"Ferrara","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"15Hematology\/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-7828","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"3The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"9674","key":"2024070913003146500_bib1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"22","key":"2024070913003146500_bib2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2024070913003146500_bib3","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","article-title":"The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease","volume":"3","author":"Srinagesh","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2024070913003146500_bib4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"issue":"20","key":"2024070913003146500_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2024070913003146500_bib6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024070913003146500_bib7","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2024070913003146500_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study","volume":"55","author":"Escamilla Gomez","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024070913003146500_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A\u00a0refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024070913003146500_bib10","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A\u00a0prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"issue":"25","key":"2024070913003146500_bib11","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"issue":"20","key":"2024070913003146500_bib12","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"2024070913003146500_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"308","key":"2024070913003146500_bib14","doi-asserted-by":"crossref","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","article-title":"ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"11","key":"2024070913003146500_bib15","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1172\/JCI99261","article-title":"Survival signal REG3alpha prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease","volume":"128","author":"Zhao","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2024070913003146500_bib16","doi-asserted-by":"crossref","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI Insight"},{"issue":"12","key":"2024070913003146500_bib17","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/bloodadvances.2022007296","article-title":"Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification","volume":"6","author":"Etra","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2024070913003146500_bib18","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2023009929","article-title":"The utility of biomarkers in acute GVHD prognostication","volume":"7","author":"Spyrou","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2024070913003146500_bib19","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1182\/bloodadvances.2023009885","article-title":"Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2024070913003146500_bib20","first-page":"2771","article-title":"Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis","volume":"141","author":"Socie","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2024070913003146500_bib21","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","article-title":"The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD","volume":"125","author":"Reichenbach","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3488\/2233878\/blooda_adv-2024-012561-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3488\/2233878\/blooda_adv-2024-012561-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:00:57Z","timestamp":1720515657000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3488\/515781\/The-MAGIC-algorithm-probability-predicts-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012561","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}